November 18, 2026
Health news, explained with evidence
LIVE

Recent Advances and Retractions in Neurology: A Weekly Overview

🧠 AI Analysis 2 min read 👁 3

Recent medical studies published across multiple journals highlight new blood tests for dementia risk, diabetes links to Alzheimer's, and significant retracting of Parkinson's data.

Recent Advances and Retractions in Neurology: A Weekly Overview🧠AI Analysis

Photo: medpagetoday.com

Key points

  • Blood levels of p-tau217 linked to multi-year dementia risk.
  • Type 2 diabetes associated with a 53% higher Alzheimer's risk.
  • Cell Reports retracts 2025 study over data manipulation.

Recent neurological research highlights several developments in neurodegenerative disease biomarkers, risk factors, and scientific accountability. According to a study published in JAMA Neurology, elevated blood levels of phosphorylated tau 217 (p-tau217) among cognitively unimpaired individuals were linked to a higher 5- and 10-year risk of developing mild cognitive impairment and dementia. In related findings published in Alzheimer's Research & Therapy, a systematic review and meta-analysis indicated that individuals with type 2 diabetes face a 53% higher risk of Alzheimer's disease.

Other findings touched upon sleep and brain mechanics. Research published in Nature Aging demonstrated that cerebrospinal fluid waves assisting in brain debris clearance during sleep are significantly reduced in older adults. Meanwhile, electroencephalography data featured in Science Translational Medicine revealed that sleep-like slow waves during waking hours occur more frequently in Parkinson's disease patients and correlate with hallucinations and cognitive impairment.

On the diagnostic front, a plasma immunoassay for endogenously cleaved microtubule-binding region tau (eMTBR-tau), published in JAMA, successfully identified advanced tau pathology across four cohorts with results comparable to mass spectrometry. Additionally, the scientific record saw corrections as Cell Reports retracted a 2025 study on neurologic disease cell and mouse models by Denali Therapeutics scientists, citing data manipulation.

What to know

  • Blood biomarkers like p-tau217 and eMTBR-tau are emerging as potential tools for predicting future cognitive decline and identifying advanced pathology.
  • Observational studies and meta-analyses suggest strong correlations, such as the link between type 2 diabetes and Alzheimer's risk, but do not establish direct causation.
  • Scientific rigor remains under scrutiny following high-profile retractions over data manipulation.

Always consult a qualified healthcare provider regarding personal health concerns or decisions related to cognitive health and chronic conditions.

Source medpagetoday.com — medpagetoday.com/neurology/generalneurology/123918 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.